XORTX Therapeutics Inc.

Contributing Author

Recent Articles by XORTX Therapeutics Inc.

Feb-04	XORTX Provides Update on Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems XRTX -17.71% XRTX GlobeNewswire
Dec-31	XORTX Announces Pioneering Research on Genome-Wide Pathogenic Pathways in Gout and Provides a Corporate Update XRTX GlobeNewswire
Oct-29	XORTX Announces Closing of US$1.1 Million Registered Direct Offering XRTX GlobeNewswire
Oct-21	XORTX Announces Pricing of US$1.1 Million Registered Direct Offering XRTX GlobeNewswire
Oct-20	XORTX Issues Correction Notice and XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency XRTX GlobeNewswire
Oct-20	XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency XRTX -31.82% GlobeNewswire
Oct-17	XORTX Announces Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems XRTX +29.41% GlobeNewswire
Sep-04	Join XORTX for an Exclusive Live Investor Webinar and Q&A Session on September 10 XRTX GlobeNewswire
Sep-03	XORTX Initiates IND Preparation for XORLO in Gout Program XRTX GlobeNewswire
Aug-08	XORTX Completes USD $114,500 Private Placement XRTX GlobeNewswire
Aug-07	XORTX Provides Corporate Update and Planned Activities for 2025 / 2026 XRTX +5.41% GlobeNewswire
Jul-31	XORTX Announces USD $114,500 Private Placement XRTX GlobeNewswire
Jul-22	XORTX Completes Non-Brokered Private Placement of Units XRTX -5.13% XRTX GlobeNewswire
Jun-26	XORTX Announces USD $925,000 Private Placement XRTX GlobeNewswire
May-19	XORTX Announces USD $3 Million Offering XRTX -14.02% GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved.